Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme
Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme
复制标题
DOI：
10.1016/j.ejca.2014.03.001
复制
发表时间：
2014-07-01
影响因子：
8.4
通讯作者：
Danson, S. J.
中科院分区：
文献类型：
--
作者：
Khan, F.;Ottensmeier, C.;Danson, S. J.
简介：阿法替尼治疗既往对厄洛替尼或吉非替尼敏感的非小细胞肺癌（NSCLC）患者的无进展生存期（PFS）。本研究调查了阿法替尼的经验，根据指定的患者使用（NPU）programmes.Patients和方法：收集了63例患者的回顾性数据，包括人口统计学资料，剂量，毒性和临床疗效。结果：反应率和中位PFS分别为14.3%和2.6个月。腹泻和皮疹是最常见的毒性，46%的患者需要减少剂量和41%的剂量delay.Conclusions：疗效和安全性的NPU计划是一致的LUX肺1试验。(C)2014爱思唯尔有限公司版权所有。
Introduction: Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to erlotinib or gefitinib. This study investigated experience of afatinib under a Named Patient Use (NPU) programme.Patients and methods: Retrospective data for 63 patients were collected, including demographics, dose, toxicity and clinical efficacy.Results: Response rate and median PFS were 14.3% and 2.6 months, respectively. Diarrhoea and rash were the most common toxicities; 46% of patients required a dose reduction and 41% had a dose delay.Conclusions: Efficacy and safety in the NPU programme are consistent with the LUX-Lung 1 trial. (C) 2014 Elsevier Ltd. All rights reserved.